- Home
- NRXS
NRXS
Neuraxis Inc.
as 12-18-2024 1:40pm EST
Stocks
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | CARMEL |
| Market Cap: | 17.3M | IPO Year: | 2023 |
| Target Price: | N/A | AVG Volume (30 days): | 25.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.00 - $3.89 | Next Earning Date: | 11-12-2024 |
| Revenue: | $2,456,219 | Revenue Growth: | -3.36% |
| Revenue Growth (this year): | 383.16% | Revenue Growth (next year): | N/A |
Latest Neuraxis Inc. News
NRXS Breaking Stock News: Dive into NRXS Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation
Zacks
a month ago
NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage
GlobeNewswire
a month ago
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues
GlobeNewswire
a month ago
NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024
MT Newswires
a month ago
NeurAxis' IB-Stim Nerve Stimulator for Abdominal Pain Relief Gets New FDA Clearance
GlobeNewswire
a month ago
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market
GlobeNewswire
2 months ago
NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024
GlobeNewswire
2 months ago
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation
Compare NRXS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NRXS Neuraxis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.